Clinical Trials
7
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
- Conditions
- Acute Kidney Injury Due to SepsisAcute Kidney Injury
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- SeaStar Medical
- Target Recruit Count
- 300
- Registration Number
- NCT06517810
- Locations
- 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
🇺🇸UCSF Benioff Children's, San Francisco, California, United States
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
- Conditions
- Acute Kidney Injury
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- SeaStar Medical
- Target Recruit Count
- 200
- Registration Number
- NCT05758077
- Locations
- 🇺🇸
University of Alabama Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸Central Arkansas Veterans Healthcare, Little Rock, Arkansas, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19
- Conditions
- Continuous Renal Replacement TherapyCOVID-19Pulmonary Edema
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- SeaStar Medical
- Registration Number
- NCT04537975
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
- Conditions
- ARDSCOVIDAKI
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- SeaStar Medical
- Target Recruit Count
- 22
- Registration Number
- NCT04395911
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
- Conditions
- Acute on Chronic Systolic Congestive Heart FailureCardiorenal Syndrome
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- SeaStar Medical
- Target Recruit Count
- 20
- Registration Number
- NCT03836482
- Prev
- 1
- 2
- Next
News
SeaStar Medical's SCD Therapy Receives $2 Million DoD Grant for Military Burn and Sepsis Research
The AREVA Institute secured a prestigious $2 million Department of Defense grant to evaluate SeaStar Medical's Selective Cytopheretic Device therapy for treating severe burns, inhalation injury, and sepsis in warfighters.
SeaStar Medical Reaches Halfway Enrollment Milestone in Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury
SeaStar Medical has reached the halfway point in its NEUTRALIZE-AKI pivotal trial, enrolling 100 of the planned 200 adult patients with acute kidney injury requiring continuous renal replacement therapy.
UNMC Researcher to Present Groundbreaking ICU Care Bundle Implementation Study at NIH
Dr. Michele Balas from UNMC College of Nursing will present research on implementing the ABCDEF Bundle in intensive care units at the NIH Pragmatic Trials Collaboratory Grand Rounds.
SeaStar Medical Secures $6M Funding to Advance Novel Extracorporeal Inflammation Therapies
SeaStar Medical has successfully closed a $6 million registered direct offering, strengthening its financial position to advance its cell-directed extracorporeal therapy development.
FDA Approves SeaStar Medical's SCD-ADULT Feasibility Study for Cardiorenal Syndrome
The FDA has approved SeaStar Medical's IDE application for SCD-ADULT to assess safety and efficacy in reducing inflammation in adults with acute heart failure.
SeaStar Medical's Selective Cytopheretic Device Receives FDA Breakthrough Designation for ESRD Inflammation
SeaStar Medical's Selective Cytopheretic Device (SCD) has been granted Breakthrough Device designation by the FDA for treating inflammation in end-stage renal disease (ESRD).
SeaStar Medical's SCD Shows Multibillion-Dollar Market Potential Across Multiple Indications
SeaStar Medical estimates a $25 to $33 billion U.S. market for its Selective Cytopheretic Device (SCD) across five indications, pending FDA approvals.
SeaStar Medical's SCD Receives FDA Breakthrough Designation for Chronic Dialysis
SeaStar Medical's Selective Cytopheretic Device (SCD) has received its fourth FDA Breakthrough Device Designation for treating chronic systemic inflammation in end-stage renal disease patients undergoing chronic hemodialysis.
SeaStar Medical's SCD Receives FDA Breakthrough Device Designation for ESRD Treatment
SeaStar Medical's SCD device receives FDA Breakthrough Device Designation for treating chronic systemic inflammation in end-stage renal disease (ESRD) patients undergoing hemodialysis.
SeaStar Medical's SCD Receives FDA Breakthrough Device Designation for Chronic Dialysis
SeaStar Medical's Selective Cytopheretic Device (SCD) has received Breakthrough Device Designation from the FDA for treating chronic systemic inflammation in end-stage renal disease (ESRD) patients undergoing chronic hemodialysis.